Abstract: Objective To investigate the efficacy of Fendong combined with Kuntai capsule in the treatment of perimenopausal syndrome and its influence on the levels of 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine (DA). Methods From March 2020 to May 2022, 80 patients with perimenopausal syndrome were divided into two groups with 40 cases in each group by random number table method.The control group was treated with fenmorton, and the experimental group was treated with Fenmorton combined with Kuntai capsule. The clinical efficacy and safety were evaluated. The levels of sex hormones [Estradiol (E₂), follicle-stimulating hormone (FSH), luteinizing hormone (LH)] and neurotransmitters [5-HT, NE, DA] were detected before and after treatment. Results The total response rate in the test group (97.50%) was significantly higher than that in the control group (80.00%) (P<0.05). The E₂ level in the post-treatment group was significantly lower than that in the control group (P<0.05), and the FSH and LH levels in the two groups (P>0.05). NE and DA levels in the posttreatment test group were significantly higher than those in the control group (P<0.05), and there was no difference in 5-HT levels between the two groups (P>0.05). Conclusion The treatment of perimenopausal syndrome has good curative effect, safe and reliable, and can effectively improve E₂ level and neurotransmitter level.

Key words: perimenopausal syndrome, femerton, kuntai capsule, neurotransmitter, sex hormone